Hemabate (carboprost tromethamine)

Last reviewed October 24, 2026 · Source: First Databank (FDB) drug data

Overview

Stimulates uterine smooth muscle; synthetic derivative of prostaglandin F2alpha.

Elicits pharmacologic responses usually produced by endogenous prostaglandin F2alpha; more potent and has longer duration of activity on the uterus than prostaglandin F2alpha.

Increases the amplitude and frequency of uterine contractions throughout pregnancy; uterine response to the drug increases with the duration of pregnancy.

After delivery, uterine contractions impede uterine blood flow.

Produces cervical dilation.

Produces contraction of vascular smooth muscle; may result in increased blood pressure.

Causes stimulation of the smooth muscle of the GI tract, increasing GI motility.

Stimulates transient bronchoconstriction in some patients.

Generic name: carboprost tromethamine

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Hemabate

Intelligence content is not available yet.

Indications

The following indications are listed for Hemabate:

Abortion
Postpartum Hemorrhage

Also known as: Postpartum Bleeding, Termination Of Pregnancy.

Dosing

Available as carboprost tromethamine; dosage is expressed in terms of carboprost.

Closely adhere to recommended dosage. Dosage determined by uterine response.

Drug interactions

May increase activity of other oxytocic agents; concomitant use not recommended.

Contraindications

Known hypersensitivity to carboprost.

Acute pelvic inflammatory disease.

Active cardiac, pulmonary, renal, or hepatic disease.

Adverse reactions

Vomiting, diarrhea, nausea, fever, flushing.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a ZIP code to view available health plans.